Injective ETF Approved: INJ Jumps 22% as Nasdaq Lists Canary's Staked INJC — 5 Numbers That Decide $10 or $6.50

INJ Jumped 22% in Two Days — But You Still Can't Buy the ETF

Injective (INJ) is up roughly 22% since bottoming at $6.82 on November 3, trading near $8.30 on Thursday, November 5, 2026 — after Nasdaq approved the listing of Canary Capital's Staked INJ ETF under the ticker INJC. It was the biggest gainer in the CoinDesk 100, rising about 6% since midnight UTC and around 10% over 24 hours, while Bitcoin steadied near $80,250 and Ethereum traded around $2,415. Here is the part most headlines skip: the ETF is approved to list, but it cannot trade yet. Public trading only begins once the fund's S-1 registration statement becomes effective with the U.S. Securities and Exchange Commission — and until then, INJ's rally is running on an approval, not on inflows. This article explains what Nasdaq actually approved, what the fund costs, how the staking works, and the five numbers that decide whether INJ pushes toward $10 or falls back to $6.50.

What Nasdaq Actually Approved

On November 3, 2026, Canary Capital filed a Form 8-A with the SEC stating that Nasdaq had received and approved its application to list shares of the Canary Staked INJ ETF. The fund will trade under the ticker INJC once it launches, making it the first U.S.-listed staked product for Injective's native token. The news broke publicly on November 4, and INJ has climbed every day since.

The distinction matters, and it is the single most misunderstood fact about this story. Exchange approval to list is a separate step from SEC registration of the product. The Form 8-A does not mean the regulator has endorsed the fund as an investment, and it does not authorize share sales. Trading remains pending until the S-1 registration statement becomes effective, plus final operational readiness. Canary filed its latest amended S-1 on October 23, 2026. Until the SEC declares that document effective, INJC is a ticker without a trade button.

That is not a reason to dismiss the approval. Nasdaq listing approval is still a genuine institutional milestone: it means the exchange has vetted the product's structure and is ready to host it. It also puts Injective on a short list. Canary first announced plans for the staked INJ ETF on October 6, and a second INJ ETF application — from 21Shares — is also in the pipeline. The race to list the first regulated Injective product in the United States now has a clear leader.

How the INJC Fund Works: 90% Staked, 1.10% Fee, 30% of Rewards to Fees

INJC is designed to hold spot INJ and stake most of it. Under normal conditions, the fund targets staking at least 90% of its INJ holdings, keeping the remainder as a buffer for redemptions and expenses. Staking rewards are reinvested, so the fund is meant to give brokerage-account investors exposure to INJ's price plus the network's staking rewards — without running a validator or holding the token directly.

The plumbing is fully institutional. BitGo Bank & Trust holds the INJ, Luganodes runs the staking, and U.S. Bank keeps the cash. That structure is the point: pension funds, RIAs and retail investors who cannot or will not self-custody crypto can now buy INJ exposure through a normal brokerage account, with staking yield baked in.

But the costs deserve a hard look, because they are heavier than they first appear. The fund charges a 1.10% annual sponsor fee. On top of that, the prospectus expects 30% of gross staking rewards to go to fees shared by the sponsor, the staking provider and the custodian. In other words, an investor keeps roughly 70% of the staking yield the fund earns — before the 1.10% fee on assets. Anyone comparing INJC's yield to staking INJ directly should do the arithmetic first: direct staking keeps 100% of the rewards (minus a validator's commission, typically far below 30%), while the ETF route trades convenience and brokerage access for a meaningful haircut. For a primer on how staking yields actually work, see our guide to crypto staking explained.

INJ Price: From $6.82 to $8.30 in 48 Hours

The price action tells the story in one chart. INJ bottomed at $6.82 on November 3 — the same day Canary filed the Form 8-A. By Thursday morning it was trading near $8.30, a gain of roughly 22% in two days, with a market capitalization of approximately $815–$820 million. CoinDesk reported INJ at $8.4285, leading the CoinDesk 100, up around 10% over 24 hours.

Context keeps the move honest. INJ is still far below its March 2024 peak above $50, so a 22% bounce from the lows is a recovery rally inside a much longer drawdown, not a return to all-time highs. The token also rallied into a friendly tape: the broader market rebounded after the U.S. midterm elections, with Bitcoin reclaiming $80,000, Ethereum jumping 7.5% to about $2,428, and total crypto market capitalization rising 5.1% to $2.79 trillion. INJ outperformed, but it did not rally alone.

Technicals add a note of caution. Analysts covering the move flag an overbought RSI and an unresolved death cross on INJ's chart — signals that leave the rally unconfirmed until the price holds above its breakout levels. The next test is whether INJ can defend the $7.64 area it broke above during the rally, or whether the ETF news fades into a sell-the-news dip before the S-1 goes effective.

INJC vs. Holding INJ Directly: The Comparison That Matters

The real question for most readers is not whether the ETF exists, but whether it is the right way to own INJ. The answer depends on what you value — convenience or yield — and the table below makes the trade-off explicit.

Feature	INJC ETF (once trading)	Holding INJ directly
Access	Any brokerage account, no crypto exchange needed	Crypto exchange or DEX, plus a wallet
Staking	Fund stakes ≥90% of holdings; rewards reinvested	You stake yourself or delegate to a validator
Share of staking rewards kept	~70% (30% goes to fund fees)	~100% minus validator commission
Annual fee	1.10% sponsor fee	No fund fee; network fees only
Custody	BitGo Bank & Trust (institutional)	Your wallet — your keys, your risk
Tradability	Only after S-1 goes effective; market hours	24/7 on exchanges and DEXs
Tax reporting	Standard brokerage 1099-style reporting	You track every transaction yourself

The ETF wins on access and simplicity; direct holding wins on yield and control. Investors who already hold crypto in a wallet and are comfortable staking will likely keep more of their rewards by holding INJ directly — our best crypto wallets in 2026 guide covers self-custody options, and our What Is a DEX? explainer covers buying without a centralized exchange. Investors who want INJ in a retirement account or a managed portfolio will find INJC the only practical route — and for them, the fee haircut is the price of admission.

Bull, Base, Bear: 3 Scenarios for INJ

Price predictions are not promises. The levels below are analysis based on the levels traders are watching this week — the $6.82 low, the $7.64 breakout area, and the $8.30–$8.43 zone where INJ trades now — combined with the S-1 timeline.

Scenario	Trigger	Price level	Probability read
Bull	S-1 goes effective fast; INJC launches with strong day-one volume; Bitcoin holds $80,000 into Friday's jobs report	$9.50–$10.00	Needs a second catalyst — the listing alone is priced in
Base	S-1 timing stays unclear; INJ consolidates above the breakout; market waits for the jobs report	$8.00–$8.50 range	Most likely near-term path while trading is pending
Bear	INJ loses $7.64; ETF excitement fades; Bitcoin slips back under $78,000	$6.82 retest, then lower	Live risk while the RSI stays overbought

The $10 level is the bull case's magnet: a round number, roughly 20% above current prices, and a level that would confirm the ETF rally as a trend change rather than a news spike. The $6.82 low is the bear case's tripwire: losing it would erase the entire ETF move and hand the narrative back to the sellers. Between them, $7.64 is the line in the sand — the breakout level INJ recovered above during the rally. Holding it keeps the bull case alive; losing it says the market bought the rumor and is selling the wait.

What Most People Get Wrong About the Injective ETF

Myth 1: "The ETF is approved, so you can buy it now." Wrong. Nasdaq approved the listing; the SEC has not yet made the S-1 effective. No shares can be sold until that happens. Anyone claiming to sell you INJC today is either confused or running a scam.

Myth 2: "ETF approval means the SEC endorses INJ." Wrong. Listing approval is an exchange decision about the product's structure. It is not a regulatory blessing of the token, and the 8-A filing says so in substance. The SEC's separate registration process is still open.

Myth 3: "Staking through the ETF pays the same as staking yourself." Wrong. The fund keeps 30% of gross staking rewards for fees, on top of a 1.10% annual sponsor fee. Convenience costs yield — do the math before assuming the ETF is the cheaper route.

Myth 4: "INJ's 22% jump means institutions are already buying." Unproven. The rally is driven by the announcement and by a broad post-election market rebound. Real institutional flow can only be measured once INJC actually trades and publishes daily flow data. Until then, the 22% is a sentiment move, not a flow move.

Myth 5: "This is the first crypto ETF with staking." Not quite. It is the first U.S.-listed staked product for Injective specifically, and one of the first staked single-asset altcoin ETFs to reach listing approval. Staked ETH products have been working through the same pipeline — INJ is early, not first overall. For context on how staking yields compare across networks, see our Ethereum vs Solana staking comparison.

Why Injective, Why Now: The Bigger ETF Wave

INJC did not appear from nowhere. It is part of a wave of single-asset altcoin ETF filings that followed the success of spot Bitcoin and Ethereum ETFs, and it arrives in a week when crypto ETF flows are turning. U.S. spot Bitcoin ETFs took in $74.6 million on November 4, ending a three-day outflow streak, with Fidelity's FBTC attracting $236.7 million in a single day even as BlackRock's IBIT lost $201.2 million. Issuers are racing to be first in every altcoin category because the first fund in a category tends to keep most of the assets.

Injective's pitch to that race is its design: a Layer-1 blockchain built specifically for decentralized finance, with on-chain order books and derivatives trading at its core. That makes a staked INJ ETF a bet not just on a token, but on DeFi infrastructure reaching brokerage accounts. The 21Shares Injective ETF application shows the category is competitive — if Canary's S-1 stalls, a rival could still win the launch race.

The timing also helps. The post-midterm rally lifted the whole market — Bitcoin up 5.4%, Ethereum up 7.5% in 24 hours, fear and greed back to neutral at 50 — and INJ's announcement landed on top of that wave. The question now is whether the S-1 goes effective while the momentum lasts, or whether the wait stretches into weeks and the rally cools. Friday's U.S. jobs report is the next scheduled macro catalyst, and Bitcoin's 81% implied odds of a December Fed rate hike hang over every risk asset.

5 Numbers That Decide $10 or $6.50

1. $8.30 — the price to hold. INJ trades near $8.30 after a 22% run from $6.82. Holding above $8 keeps the breakout intact; a daily close below it starts the fade.

2. 90% — the staking target. INJC plans to stake at least 90% of its INJ under normal conditions. That is the fund's core promise: price exposure plus yield. Watch whether the final S-1 keeps that commitment.

3. 30% — the rewards haircut. Nearly a third of gross staking rewards go to the sponsor, staking provider and custodian. It is the number that decides whether the ETF or direct staking wins for yield-focused holders.

4. 1.10% — the annual fee. High next to spot Bitcoin ETFs, which charge a fraction of that. The fee is the cost of the staking wrapper and the altcoin category — and the reason direct holders keep more.

5. $815 million — the market cap. INJ's market capitalization of roughly $815–$820 million is small next to the majors. Small caps move fast on good news — and give it all back fast when the news stalls. That is why the S-1 timeline, not the listing headline, is the number that matters most.

What to Watch Next

Three dates and data points decide what happens from here. First, the S-1 effectiveness: the day the SEC declares Canary's registration effective, INJC can begin trading, and the first days of flow data will show whether institutions actually want staked INJ exposure. Second, Friday's U.S. jobs report on November 6 — the next macro catalyst, with Bitcoin sitting near $80,400 and traders watching whether the post-election rally holds. Third, INJ's own chart: $7.64 as support, $8.43 as the recent high, and $10 as the round-number target if momentum returns.

For readers considering exposure, the practical checklist is short: never buy a "pre-launch INJC" from anyone — the fund cannot trade yet; compare the ETF's 1.10% fee plus 30% rewards haircut against direct staking before choosing a route; size any position for a token that can move 22% in two days in either direction; and keep an eye on the 21Shares application, which could change the competitive picture overnight. New to buying crypto outright? Our beginner's guide to buying crypto walks through exchanges, wallets and first-purchase safety checks, and our best altcoins to buy in November 2026 ranking puts INJ's move in the context of the wider altcoin market.

FAQs

What is the Injective ETF (INJC)?

INJC is Canary Capital's Staked INJ ETF, a fund designed to hold Injective's INJ token and stake at least 90% of its holdings for additional rewards. Nasdaq has approved its listing under the ticker INJC, but it cannot trade until its S-1 registration statement becomes effective with the SEC.

Can I buy the INJ ETF now?

No. Nasdaq's listing approval is not the start of trading. The fund's S-1 must first become effective with the SEC, and Canary must complete final operational readiness. Any offer to sell you INJC shares before that happens should be treated as a scam.

Why did INJ price jump 22%?

INJ rose from a $6.82 low on November 3 to around $8.30 on November 5 after Nasdaq approved the INJC listing, helped by a broader post-U.S.-midterm crypto rally that lifted Bitcoin above $80,000 and Ethereum 7.5%. INJ led the CoinDesk 100 gainers on the news.

How much does the INJ ETF cost?

The fund charges a 1.10% annual sponsor fee, and the prospectus expects 30% of gross staking rewards to go to fees shared by the sponsor, the staking provider and the custodian. Investors keep roughly 70% of the staking yield the fund earns.

Is staking INJ directly better than buying the ETF?

For yield, usually yes: direct staking keeps nearly all rewards minus a validator's commission, while the ETF takes 30% of rewards plus a 1.10% fee. For convenience, brokerage access and tax reporting, the ETF wins. The right choice depends on whether you already hold crypto and are comfortable with self-custody.

What is Injective (INJ)?

Injective is a Layer-1 blockchain built for decentralized finance, with on-chain order books and derivatives trading. INJ is its native token, used for staking, governance and fees. The token's market capitalization is roughly $815–$820 million.

Conclusion

Nasdaq's approval of the Canary Staked INJ ETF is a real milestone for Injective — the first U.S.-listed staked INJ product, a 22% price jump to $8.30, and a place at the front of the altcoin ETF race. But the milestone comes with an asterisk the size of the trade: the fund cannot sell a single share until its S-1 goes effective, its 1.10% fee and 30% rewards haircut make it a costly way to earn staking yield, and INJ's technicals warn the rally is unconfirmed. The bull case needs the S-1 to go effective while momentum lasts and INJ to hold $7.64 on the way to $10. The bear case needs only patience: if the registration drags and Bitcoin slips under $78,000, the $6.82 low is back in play. Watch the S-1, watch $7.64, and don't pay anyone for INJC before it exists.

Disclaimer: This article is for educational purposes only and is not investment advice. Cryptocurrency prices are volatile; do your own research before investing.